Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.

Tim Flaadt,Ruth L Ladenstein,Martin Ebinger,Holger N Lode,Helga Björk Arnardóttir,Ulrike Poetschger,Wolfgang Schwinger,Roland Meisel,Friedhelm R Schuster,Michaela Döring,Peter F Ambros,Manon Queudeville,Jörg Fuchs,Steven W Warmann,Jürgen Schäfer,Christian Seitz,Patrick Schlegel,Ines B Brecht,Ursula Holzer, Tobias Feuchtinger,Thorsten Simon,Johannes H Schulte,Angelika Eggert,Heiko-Manuel Teltschik,Toni Illhardt,Rupert Handgretinger,Peter Lang

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

Cited 5|Views66
No score
Abstract
DB therapy after haplo-SCT in patients with rHR-NB is feasible, with low risk of inducing GvHD, and results in long-term remissions likely attributable to increased antineuroblastoma activity by donor-derived effector cells.
More
Translated text
Key words
relapsed neuroblastoma,transplantation,low-dose,stem-cell
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined